NASDAQ · GERN
Healthcare · Biotechnology
$1.30
Up+$0.00 (+0.00%)
Updated Sep 22, 2026, 3:30 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GERN closed at $1.30 after 20 trading sessions, down 14.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $1.30 | $1.31 | $1.28 | $1.30 | 5.9M |
| Sep 18, 2026 | $1.32 | $1.33 | $1.29 | $1.30 | 17.24M |
| Sep 17, 2026 | $1.32 | $1.34 | $1.30 | $1.32 | 9.82M |
| Sep 16, 2026 | $1.32 | $1.33 | $1.27 | $1.29 | 11.44M |
| Sep 15, 2026 | $1.37 | $1.37 | $1.30 | $1.31 | 16.49M |
| Sep 14, 2026 | $1.36 | $1.395 | $1.344 | $1.37 | 12.12M |
| Sep 11, 2026 | $1.385 | $1.41 | $1.34 | $1.35 | 9.87M |
| Sep 10, 2026 | $1.39 | $1.405 | $1.36 | $1.37 | 7.69M |
| Sep 9, 2026 | $1.50 | $1.51 | $1.40 | $1.40 | 9.24M |
| Sep 8, 2026 | $1.55 | $1.58 | $1.50 | $1.51 | 8.31M |
| Sep 4, 2026 | $1.49 | $1.59 | $1.46 | $1.57 | 11.48M |
| Sep 3, 2026 | $1.58 | $1.60 | $1.48 | $1.51 | 14.23M |
| Sep 2, 2026 | $1.49 | $1.62 | $1.48 | $1.59 | 26.89M |
| Sep 1, 2026 | $1.47 | $1.495 | $1.46 | $1.48 | 7.89M |
| Aug 31, 2026 | $1.50 | $1.51 | $1.45 | $1.49 | 7.25M |
| Aug 28, 2026 | $1.53 | $1.53 | $1.49 | $1.51 | 7.42M |
| Aug 27, 2026 | $1.54 | $1.56 | $1.50 | $1.53 | 7.88M |
| Aug 26, 2026 | $1.58 | $1.58 | $1.50 | $1.53 | 9.12M |
| Aug 25, 2026 | $1.55 | $1.59 | $1.50 | $1.55 | 9.84M |
| Aug 24, 2026 | $1.53 | $1.55 | $1.44 | $1.52 | 13.11M |
The latest Smart Investors Daily articles mentioning GERN.
GERN research
Company profile and research snapshot.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2025 | Needham | Buy | — |
| Jul 10, 2025 | Goldman Sachs | Sell | — |
| May 8, 2025 | Scotiabank | Sector Perform | — |
| Mar 12, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 12, 2025 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 13, 2026
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur
Yahoo · Sep 2, 2026
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen
ChartMill · Aug 5, 2026
Geron's Q2 2026 results mixed: RYTELO revenue beats estimates, but wider adjusted loss and flat guidance weigh on shares.
SeekingAlpha · Aug 5, 2026
Geron Corporation (GERN) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsDawn Schottlandt - Senior Vice President of Investor Relations...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GERN.
